Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
26.95
+0.61 (2.30%)
Oct 19, 2026, 1:05 PM EDT - Market open
Amylyx Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
136
Market Cap
3.38B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 87.37M | -293.42M | -77.06% |
| Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
| Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
| Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
| Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
| Dec 31, 2019 | 1.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.85B |
| Perrigo Company | 4.14B |
| Indivior Pharmaceuticals | 1.33B |
| Trulieve Cannabis | 1.14B |
| Prestige Consumer Healthcare | 1.10B |
| BioCryst Pharmaceuticals | 940.61M |
| Supernus Pharmaceuticals | 830.44M |
| HUTCHMED (China) | 549.12M |
AMLX News
- 4 days ago - Amylyx price target raised to $39 from $32 at Citi - TheFly
- 13 days ago - Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting - Business Wire
- 19 days ago - Amylyx Pharmaceuticals Transcript: Stifel 2026 Virtual Cardiometabolic Forum - Transcripts
- 26 days ago - Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum - Business Wire
- 4 weeks ago - Amylyx Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 5 weeks ago - Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference - Business Wire
- 7 weeks ago - 20 stocks likely to lose money even if the bull market continues - Market Watch
- 7 weeks ago - Amylyx price target raised to $57 from $55 at Guggenheim - TheFly